文献速递艾滋病与性传播感染

HIV-1 3'-多嘌呤 tract G-串特定突变导致整合酶链转移抑制剂耐药

Specific mutations in the HIV-1 G-tract of the 3'-polypurine tract cause resistance to integrase strand transfer inhibitors.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

研究通过构建含3'-PPT G-串单突变或双突变的感染性克隆,在TZM-bl细胞单周期实验中检测其对第一代和第二代整合酶链转移抑制剂的敏感性。结果显示第5位单突变不影响耐药,而第2位与第5位双突变增加耐药并出现最大抑制百分比平台。

要点

  • 3'-PPT G-串第5位单突变(GGG GTG)对INSTI耐药无影响。
  • 第2位与第5位双突变(GCG GTG和GTG GTG)增加对INSTI的耐药。
  • 双突变株剂量反应曲线最大抑制百分比出现平台,符合非竞争性抑制机制。

核心结论

  • 3'-PPT G-串第2位和第5位突变可能导致复杂耐药机制,而非简单影响INSTI与整合酶活性位点结合。

研究设计与样本

  • 构建含3'-PPT G-串单突变或多突变的感染性克隆,在TZM-bl细胞中采用单周期实验检测感染性和对第一代及第二代INSTI的敏感性。

主要发现

  • 3'-PPT G-串第5位胸苷(T)单突变(GGG GTG)对INSTI耐药无影响。
  • 第2位胞苷(C)或胸苷(T)与第5位胸苷(T)双突变(GCG GTG和GTG GTG)增加对INSTI的耐药,剂量反应曲线最大抑制百分比出现平台,符合非竞争性抑制机制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In vitro selection experiments identified viruses resistant to integrase strand transfer inhibitors (INSTIs) carrying mutations in the G-tract (six guanosines) of the 3'-polypurine tract (3'-PPT). A clinical study also reported that mutations in the 3'-PPT were observed in a patient receiving dolutegravir monotherapy. However, recombinant viruses with the 3'-PPT mutations that were found in the clinical study were recently shown to be susceptible to INSTIs. OBJECTIVES: To identify the specific mutation(s) in the G-tract of the 3'-PPT for acquiring INSTI resistance, we constructed infectious clones bearing single or multiple mutations and systematically characterized the susceptibility of these clones to both first- and second-generation INSTIs. METHODS: The infectious clones were tested for their infectivity and susceptibility to INSTIs in a single-cycle assay using TZM-bl cells. RESULTS: A single mutation of thymidine (T) at the fifth position (GGG GTG) in the G-tract of the 3'-PPT had no effect on INSTI resistance. A double mutation, cytidine (C) or 'T' at the second position and 'T' at the fifth position (GCG GTG and GTG GTG), increased resistance to INSTIs, with the appearance of a plateau in the maximal percentage inhibition (MPI) of the dose-response curves, consistent with a non-competitive mechanism of inhibition. CONCLUSIONS: Mutations at the second and fifth positions in the G-tract of the 3'-PPT may result in complex resistance mechanism(s), rather than simply affecting INSTI binding at the IN active site.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Hachiya A, Kubota M, Shigemi U, et al. Specific mutations in the HIV-1 G-tract of the 3'-polypurine tract cause resistance to integrase strand transfer inhibitors. J Antimicrob Chemother. 2022. PMID: 34894227. doi:10.1093/jac/dkab448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。